Mark J. Ratain to Quinazolines
This is a "connection" page, showing publications Mark J. Ratain has written about Quinazolines.
Connection Strength
1.262
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.287
-
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60.
Score: 0.275
-
The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8.
Score: 0.274
-
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul; 46(11):2097-103.
Score: 0.084
-
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Jan; 38(1):32-9.
Score: 0.081
-
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
Score: 0.070
-
EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9.
Score: 0.058
-
Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
Score: 0.051
-
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84.
Score: 0.044
-
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 1999 Aug 01; 86(3):528-32.
Score: 0.040